本研究針對2004 年至2009 年間,臺灣32家上市、上櫃的生物科技醫療產業公司進行績效評估。研究進行四個群組(上市製藥產業、上市醫療器材產業、上櫃製藥產業以及上櫃醫療器材產業)的分析,嘗試瞭解近六年來臺灣生物科技兩大子產業-製藥業和醫療器材業,包括製藥業研發投入之成果以及醫療器材業發展之產值,績效與技術差異性之比較分析。考量的投入變數有固定資產、員工人數、經營費用-研究發展;產出變數有營業收入淨額、無形資產及市值,藉此分析生物科技公司績效之因素評估各決策單位之效率值,並利用Battese and Rao(2002)提出之共同邊界觀念,以BCC模式之產出導向為主要分析模型,歸納出影響公司績效的主要因素。研究結果顯示無論上市櫃生技公司均應將產出規模作為改善生產無效率的重點,而受評估生物科技公司TGR以上市製藥產業較靠近共同邊界者為最佳,上櫃醫療器材產業平均值最低,在TGR值變動方面,上市製藥產業變動程度較不明顯,上櫃製藥產業次之,上櫃醫療器材產業變動幅度則相對較大。
For measuring operational efficiency, this research focuses on 32 biotech pharmaceutical and biotech medical treatment firms which listed in the stock exchange and the over-the-counter (OTC) market in Taiwan. Following the metafrontier approach methodology of Battese and Rao(2002), the biotech firms are divided into four subgroups: listed biotech pharmaceutical firms, OTC biotech pharmaceutical firms, listed biotech medical treatment firms and OTC biotech medical treatment firms for realizing difference of operation efficiency and technology between subgroups. For evaluating firms’ efficiency and decision factors, fixed asset, numbers of employees and R&D expenses shown in financial report are used as input variables; net income, intangible assets and market value are used as output variables, respectively. Empirical results indicate that the listed and OCT should focus on the scale of outputs to improve their efficiency. Consulting the TGR, the TGR of the listed biotech pharmaceutical firms is the best, and the TGR of the OCT biotech medical treatment firms is the worst.